2016
DOI: 10.2217/imt.16.5
|View full text |Cite
|
Sign up to set email alerts
|

Aflibercept for the Treatment of Diabetic Macular Edema

Abstract: Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…Currently, aflibercept is licensed in the USA, EU, Japan, Switzerland, and Australia for several different vascular retinal diseases, including DMO. 28…”
Section: Pacoresmentioning
confidence: 99%
“…Currently, aflibercept is licensed in the USA, EU, Japan, Switzerland, and Australia for several different vascular retinal diseases, including DMO. 28…”
Section: Pacoresmentioning
confidence: 99%
“…Furthermore, after the loading phase (five monthly injections), the prescribing information recommends an Aflibercept injection every two months, resulting in a reduced number of injections during the first year of follow-up [ 8 , 9 , 10 ]. Therefore, Aflibercept is currently considered one of the first line therapeutic approaches in DME [ 7 , 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%